NCT03107780 2025-11-13
Testing the Ability of AMG 232 (KRT 232) to Get Into the Tumor in Patients With Brain Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
Clinical Trials
62 trialsNCT04982926 2025-10-14
A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Taiho Oncology, Inc.
Phase 1 Terminated
NCT04963413 2025-08-06
RENEW: Feasibility of CMV RNA-Pulsed Dendritic Cells Vaccines for the Treatment of Newly Diagnosed Glioblastoma Patients.
University of Florida
Phase 1 Terminated
NCT01430351 2025-05-07
Temozolomide, Memantine Hydrochloride, Mefloquine, and Metformin Hydrochloride in Treating Patients With Glioblastoma Multiforme After Radiation Therapy
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02722512 2025-02-18
Trial of Heat Shock Protein Peptide Complex-96 (HSPPC-96) Vaccine
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1 Terminated
NCT05324501 2025-02-10
MAGIC-G1
Biodexa Pharmaceuticals
Phase 1 Terminated
NCT04397679 2025-01-15
Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma
Barbara Ann Karmanos Cancer Institute
Phase 1 Terminated
NCT04404569 2024-12-20
ETERNITI
Bexion Pharmaceuticals, Inc.
Phase 1 Terminated
NCT05831995 2024-12-06
Safety and Effectiveness of ABM-168 in Adults with Advanced Solid Tumors.
ABM Therapeutics Corporation
Phase 1 Terminated
NCT01246869 2024-10-01
Assessment of Primary and Metastatic Brain Tumor Hypoxia With Fluoromisonidazole, FDG and Water
University of Utah
Phase 1 Terminated
NCT03539731 2024-08-12
[18F]DASA-23 and PET Scan in Evaluating Pyruvate Kinase M2 Expression in Patients With Intracranial Tumors or Recurrent Glioblastoma and Healthy Volunteers
Stanford University
Phase 1 Terminated
NCT04047303 2024-07-05
CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma
Celgene
Phase 1 Terminated
NCT03250299 2024-06-24
Microtubule-Targeted Agent BAL101553 and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Basilea Pharmaceutica
Phase 1 Terminated
NCT04190628 2024-05-21
Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors
ABM Therapeutics Corporation
Phase 1 Terminated
NCT02880410 2024-04-12
FLAG
Monteris Medical
Phase 1 Terminated
NCT02133183 2024-04-04
Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT03705351 2024-03-04
Tumor Treating Fields With Chemoradiation in Newly Diagnosed GBM
Providence Health & Services
Phase 1 Terminated
NCT02168270 2023-11-24
Temozolomide and Ascorbic Acid in Treating Patients With Recurrent High-Grade Glioma
University of Nebraska
Phase 1 Terminated
NCT02530502 2023-11-18
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
Northwestern University
Phase 1 Terminated
NCT02833701 2023-10-24
Bevacizumab and Ascorbic Acid in Patients Treating With Recurrent High Grade Glioma
University of Nebraska
Phase 1 Terminated
NCT04608812 2023-08-18
Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection
OncoSynergy, Inc.
Phase 1 Terminated
NCT04541225 2023-07-14
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
Nuvation Bio Inc.
Phase 1 Terminated
NCT03332355 2023-05-24
Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies - Component 2
Vanquish Oncology, Inc.
Phase 1 Terminated
NCT03714334 2023-04-07
DNX-2440 Oncolytic Adenovirus for Recurrent Glioblastoma
Clinica Universidad de Navarra, Universidad de Navarra
Phase 1 Terminated
NCT01700569 2023-02-21
FOLAGLI
Institut Cancerologie de l'Ouest
Phase 1 Terminated
NCT02664363 2023-02-17
ExCeL
Duke University
Phase 1 Terminated
NCT04782609 2022-11-17
Glio
Samus Therapeutics, Inc.
Phase 1 Terminated
NCT04489420 2022-08-10
CYNK001GBM01
Celularity Incorporated
Phase 1 Terminated
NCT02864368 2022-06-09
PERFORMANCE
Duke University
Phase 1 Terminated
NCT03422094 2021-10-27
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma
Washington University School of Medicine
Phase 1 Terminated
NCT03283631 2021-04-05
INTERCEPT
Duke University
Phase 1 Terminated
NCT02255461 2021-03-02
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
Pediatric Brain Tumor Consortium
Phase 1 Terminated
NCT03707457 2020-07-02
Biomarker-Driven Therapy Using Immune Activators With Nivolumab in Patients With First Recurrence of Glioblastoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Terminated
NCT04327011 2020-03-30
A Continuation Protocol for Patients Previously Enrolled in a Study of Toca 511
Tocagen Inc.
Phase 1 Terminated
NCT03573986 2020-02-17
Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
Abramson Cancer Center at Penn Medicine
Phase 1 Terminated
NCT02576665 2020-02-07
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Phase 1 Terminated
NCT03246113 2019-08-13
Tolerability of Cannabis in Patients Receiving Concurrent Chemoradiation for Glioblastoma
New York State Psychiatric Institute
Phase 1 Terminated
NCT04002804 2019-07-01
Dendr2
Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
Phase 1 Terminated
NCT00915694 2019-04-23
Nelfinavir Mesylate, Radiation Therapy, and Temozolomide in Treating Patients With Glioblastoma Multiforme
Abramson Cancer Center at Penn Medicine
Phase 1 Terminated
NCT00671801 2018-11-13
Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00734526 2018-11-09
Phase I Portion of Phase I/II Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT00895960 2018-11-08
Dasatinib Plus Radiation Therapy/Temozolomide in Newly-Diagnosed Glioblastoma
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02176720 2018-08-17
Response Monitoring Trial in Patients With Suspected Recurrence of Glioblastoma
The Methodist Hospital Research Institute
Phase 1 Terminated
NCT00990496 2018-05-02
A Study Using Allogenic-Cytomegalovirus (CMV) Specific Cells for Glioblastoma Multiforme (GBM)
Milton S. Hershey Medical Center
Phase 1 Terminated
NCT01702792 2018-04-04
Derivation of Tumor Specific Hybridomas
Dartmouth-Hitchcock Medical Center
Phase 1 Terminated
NCT02365662 2018-03-30
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
AbbVie
Phase 1 Terminated
NCT02254954 2018-02-27
Clinical Study on Macitentan, RT and TMZ Concurrent Therapy Followed by Maintenance Macitentan and TMZ in Newly Diagnosed Glioblastoma
Actelion
Phase 1 Terminated
NCT02510950 2017-11-17
Neoepitope-based Personalized Vaccine Approach in Patients With Newly Diagnosed Glioblastoma
Washington University School of Medicine
Phase 1 Terminated
NCT01508104 2017-08-23
Safety Study of BEZ235 With Everolimus in Subjects With Advanced Solid Tumors
University of Cincinnati
Phase 1 Terminated
NCT01526837 2017-07-12
Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
Brain & Spine Surgeons of New York
Phase 1 Terminated